Nucleoside reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signaling in endothelial cells.
Song L, Zhu X, Qiu C, Qin L, Chow S, Yu L. Nucleoside reverse transcriptase inhibitors attenuate angiogenesis and lymphangiogenesis by impairing receptor tyrosine kinases signaling in endothelial cells. The FASEB Journal 2016, 30 DOI: 10.1096/fasebj.30.1_supplement.300.2.Peer-Reviewed Original ResearchAntiretroviral therapyReceptor tyrosine kinasesEndothelial cellsRole of ARTEndothelial mitochondrial dysfunctionHIV-positive patientsMicrovascular endothelial cellsVascular endothelial cellsAortic endothelial cellsNRTI treatmentTyrosine kinaseBlood vessel growthMicrovascular functionImmunodeficiency syndromeInhibitor administrationKaposi's sarcomaClinical challengeNoncommunicable diseasesNRTIsNotch1 pathwayAngiogenic pathwaysLymphangiogenic functionTumor angiogenesisLymphatic endothelial cellsReceptor signaling